EN DE
Watch Cyclopharm Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cyclopharm Ltd (CYC) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Cyclopharm Ltd stock A$0.43, price A$0.46, that is 7.1% below the price, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000CYC5

CL Cyclopharm Ltd logo Thin data Nov 10, 2026

Cyclopharm Ltd

CYC · AU
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value A$0.4273 · Fairly valued
Expensive Growth (revenue 5y +17.1 %/yr in AUD)
Mixed vs. peers (5/10)
Quality 32/100
Loss-making · -53.2% net margin (TTM)
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Cyclopharm Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$2.90 A$0.3600 Fair Value A$0.4273 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.3600 – A$2.90 · fair‑value band A$0.3205 – A$0.5342 · the A$0.4600 price screens above the A$0.4273 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Cyclopharm in your weekly email

Every Wednesday you see whether Cyclopharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally.

Show moreShow less

The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector.

The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.

Stock analysis

Cyclopharm Ltd (CYC) currently trades at A$0.4600, while our estimate is A$0.4273, so the stock looks roughly fairly valued today (gap 7.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.3205 (bear) to A$0.5342 (bull), the price of A$0.4600 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cyclopharm Ltd reported revenue of A$32.3M in FY2025 versus A$17.7M in FY2021, a compound +16.2%/yr. Reported net income was −A$17.2M in FY2025.

Key figures

Market cap A$55.2M (≈ $38.2M) Micro · P/S ratio 1.42 · EPS (TTM) A$−0.1600 · Net margin −53.2% · Return on equity −53.9% · Return on assets (EBIT) −20.0% (5-year average) · Operating margin −48.0% · Revenue (TTM) A$34.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −7%, CYC screens richer than that median.

Fair Value

Bear A$0.3205 Fair Value A$0.4273 Bull A$0.5342
Price A$0.4600 · Downside -7.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Start year 2020 (pandemic). Over 10 years: +9.9% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−28.4% (2020) → −56.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CYC, get fair value alerts →

Compare Cyclopharm Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −7.1% · Above median
Profitability
Return on assets −37.4% · Bottom 25%
Net margin (12 months) −53.2% · Bottom 25%
Operating margin (12 months) −48.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 13.6% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.03× · Cheaper than median
P/S (12 months) 1.60× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 16
FUTURE (revenue growth)68 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs CYC
Stryker Corporation SYK $325.73 $358.46 +10% vs CYC
Boston Scientific Corporation BSX $44.02 $48.42 +10% vs CYC
DexCom, Inc DXCM $81.07 $89.18 +10% vs CYC
STERIS plc STE $256.94 $279.53 +9% vs CYC
GE HealthCare Technologies Inc GEHC $84.03 $69.92 −17% vs CYC
Edwards Lifesciences Corporation EW $104.71 $81.94 −22% vs CYC
Abbott Laboratories, ABT $110.51 $75.28 −32% vs CYC
Medtronic plc MDT $102.79 $65.61 −36% vs CYC
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs CYC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cyclopharm Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cyclopharm Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CYC

Frequently asked questions

Is Cyclopharm Ltd (CYC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.4273 versus a price of A$0.4600, about 7% lower (fairly valued).
What is the fair value of CYC?
Our estimate for Cyclopharm Ltd is A$0.4273 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.4600.
What is the quality score of CYC?
Cyclopharm Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cyclopharm Ltd (CYC)?
Our calculated price target is the estimate of A$0.4273 (as of Nov 10, 2026). Cautious scenario A$0.3205, optimistic scenario A$0.5342. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cyclopharm Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.4273, about 7% lower versus a price of A$0.4600 (fairly valued). Cautious scenario A$0.3205, optimistic scenario A$0.5342. The calculation is refreshed regularly with new filings.
What is the revenue of Cyclopharm Ltd (CYC)?
Cyclopharm Ltd reported trailing-twelve-month revenue of about A$34.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cyclopharm Ltd (CYC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cyclopharm Ltd it is A$0.4273 per share (as of Nov 10, 2026), against a price of A$0.4600.
Is Cyclopharm Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CYC trades above its calculated fair value: price A$0.4600, fair value A$0.4273, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYC?
No. The price is what the market pays today (A$0.4600); the fair value is what the company's own numbers justify (A$0.4273). For Cyclopharm Ltd the two are A$0.0327 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cyclopharm Ltd worth?
The market values Cyclopharm Ltd at about A$55.2M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.4600; our models calculate a fair value of A$0.4273 per share.
What do the bullish and bearish scenarios say about CYC?
Our models span a range for Cyclopharm Ltd: cautious scenario A$0.3205, base A$0.4273, optimistic A$0.5342 per share (as of Nov 10, 2026, price A$0.4600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cyclopharm Ltd (CYC)?
Balance-sheet figures for Cyclopharm Ltd (as of Nov 10, 2026): return on equity −53.9%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is CYC from its 52-week high?
Cyclopharm Ltd trades at A$0.4600, about 63% below its 52-week high of A$1.23 and 28% above the low of A$0.3600 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.4273 is for.
Which stocks are comparable to Cyclopharm Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cyclopharm Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.4600, calculated fair value A$0.4273 (−7%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Cyclopharm Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cyclopharm Ltd (CYC)?
The closing price on Nov 10, 2026 was A$0.4600. Our estimate is A$0.4273, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cyclopharm Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cyclopharm Ltd

How large is the market capitalisation of Cyclopharm Ltd (CYC)?
The market capitalisation of Cyclopharm Ltd is A$55.2M (≈ $38.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cyclopharm Ltd (CYC)?
The price-to-sales ratio of Cyclopharm Ltd is 1.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cyclopharm Ltd (CYC)?
Earnings per share at Cyclopharm Ltd are A$−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cyclopharm Ltd (CYC)?
The net margin of Cyclopharm Ltd is −53.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cyclopharm Ltd (CYC)?
The return on equity (ROE) of Cyclopharm Ltd is −53.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cyclopharm Ltd (CYC)?
On an EBIT basis the return on assets of Cyclopharm Ltd is −20.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cyclopharm Ltd (CYC)?
The operating margin of Cyclopharm Ltd is −48.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cyclopharm Ltd (CYC)?
Revenue at Cyclopharm Ltd is growing +13.6% versus a year earlier (3y avg +11.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cyclopharm Ltd (CYC)?
Earnings per share at Cyclopharm Ltd are growing −83.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cyclopharm Ltd (CYC) generate?
The free cash flow of Cyclopharm Ltd is −A$19.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cyclopharm Ltd (CYC) carry?
The net debt of Cyclopharm Ltd is A$8.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cyclopharm Ltd in the live analysis

One click puts Cyclopharm Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.